Thus, an adoptive immunotherapy with T cells bearing CAR is expected to be a promising tool for refractory hematological disorders.9 To apply this strategy for patients with AML, it is necessary to identify another suitable molecular target expressed on the surface of AML blasts that do not usually express CD19. This evidence concerns the gene CD19 and acute myeloid leukemia.